



CANADIAN
NEUROLOGICAL
SCIENCES
FEDERATION
FÉDÉRATION
DES SCIENCES
NEUROLOGIQUES
DU CANADA

The Journal

Canadian Journal of Neurological Sciences

Volume 38 Number 1 January 2011




figure 1




figure 2

Bipolar Electrocoagulation on Cortex after AVMs Lesionectomy for Seizure Control - pages 48-53
Yong Cao, Rong Wang, Lijun Yang, Qin Bai, Shuo Wang, Jizong Zhao

Figure 1: Before AVMs excision, the sites of discharge of epilepsy activity, which were detected by the electrodes of intraoperative EcoG, were labeled by markers on the cerebral cortex surrounding the AVM.

Figure 2: After AVM excision, the sites of discharge of epilepsy activity, which were detected by the intraoperative EcoG electrodes, were labeled by markers on the surrounding cerebral cortex.

AN INTERNATIONAL JOURNAL PUBLISHED BY THE CANADIAN NEUROLOGICAL SCIENCES FEDERATION



The official Journal of: The Canadian Neurological Society, The Canadian Neurosurgical Society, The Canadian Society of Clinical Neurophysiologists, The Canadian Association of Child Neurology



CANADIAN
NEUROLOGICAL
SCIENCES
FEDERATION
FÉDÉRATION
DES SCIENCES
NEUROLOGIQUES
DU CANADA

Join us
for the
46th
Annual Congress
of the

Canadian Neurological Sciences Federation



VANCOUVER



Surrounded by water on three sides and nestled alongside the Coast Mountain Range, Vancouver is the largest city in the province of British Columbia with over half a million residents and one of the mildest climates in Canada. Home to spectacular natural scenery and a bustling metropolitan core, Vancouver was Host City to the Olympic and Paralympic Winter Games in 2010. Whether just relaxing in a park or bike riding around the seawall, there is always something to do in Vancouver.

June 15-17, 2011
Vancouver, British Columbia

EDITORIALS

- 1** Treating the Neurosurgical Patient: Beyond the Pathology and Technology
Joseph F. Megyesi
- 3** Treatment of Patients with High-Grade Aneurysmal Subarachnoid Hemorrhage
Gary Redekop
- 4** On MR Imaging of the Intracranial Vessel Wall
Daniel M. Mandell, Manohar Shroff
- 6** Ultraviolet Radiation (UVR) and Risk of Developing Multiple Sclerosis (MS)
Sharon Warren, Kenneth G. Warren, Karen V.L. Turpin
- 8** Cause = Time
Ian Fleetwood
- 10** MRI of Tibialis Anterior as "Surrogate Measure" in Myotonic Dystrophy Type 1
Giovanni Meola

REVIEW ARTICLES

- 12** Management of Cushing's Disease After Failed Surgery - A Review
Nancy McLaughlin, Amin B. Kassam, Daniel M. Prevedello, Daniel F. Kelly
- 22** Peripheral Trauma Induced Dystonia or Post-Traumatic Syndrome?
Hrishikesh Kumar, Mandar Jog

ORIGINAL ARTICLES

- 30** Clinical Outcomes After Endovascular Coiling in High-Grade Aneurysmal Hemorrhage
Roberto Jose Diaz, John H. Wong
- 36** Proximity to the Treating Centre and Outcomes Following Subarachnoid Hemorrhage
Cian J. O'Kelly, Julian Spears, David Urbach, M. Christopher Wallace
- 41** Indocyanin Green Videoangiography Study of Hemangioblastomas
Yasuo Murai, Koji Adachi, Fumihiko Matano, Kojiro Tateyama, Akira Teramoto
- 48** Bipolar Electrocoagulation on Cortex after AVMs Lesionectomy for Seizure Control
Yong Cao, Rong Wang, Lijun Yang, Qin Bai, Shuo Wang, Jizong Zhao

- 54** Spontaneous Intracranial Hypotension: Case Series of Rare Clinical Presentations
N. Chaudhary, P. Cooper, S.P. Lownie, W. Ng, N. Duggal
- 59** In Situ Cranioplasty for Hyperostosing Meningiomas of the Cranial Vault
Orin Bloch, Michael W. McDermott
- 65** Gender, Patient Comfort and the Neurosurgical Operating Room
Rebecca Zener, Mark Bernstein
- 72** Comparison of Post-Operative Lordosis with the PEEK Cage and the Cervical Plate
Jeffrey S. Wilkinson, Sumeer A. Mann, Grant W. Stoneham, Stephen Hentschel, Daryl R. Fourney
- 78** The ASPIRE Approach for TIA Risk Stratification
S.B. Coutts, P.N. Sylaja, Y.B. Choi, A. Al-Khathami, C. SivaKumar, T.J. Jeerakathil, P.S. Sarma, M.D. Hill for the Calgary Stroke Program
- 82** Intracranial Caseating Granulomas with No Infectious Organism Detected
Amer A. Ghavanini, David G. Munoz
- 88** Neuropsychological Functioning in PLS: A Comparison with ALS
Gloria M. Grace, J.B. Orange, Ann Rowe, Karen Findlater, Morris Freedman, Michael J. Strong
- 98** A Quantitative Analysis of Suspected Environmental Causes of MS
Scott Sloka, Claudia Silva, William Pryse-Phillips, Scott Patten, Luanne Metz, V. Wee Yong
- 106** Head Pre-Cooling Improves Symptoms of Heat-Sensitive Multiple Sclerosis Patients
Luke F. Reynolds, Christine A. Short, David A. Westwood, Stephen S. Cheung
- 112** MRI of Tibialis Anterior Skeletal Muscle in Myotonic Dystrophy Type 1
Chantal Coté, Bassem Hiba, Luc J. Hebert, Christophe Vial, Jean François Remec, Marc Janier, Jack Puymirat
- 119** Multisystem Disorder in Late-Onset Chronic Progressive External Ophthalmoplegia
Gerald Pfeffer, Sandra Sirrs, N. Kevin Wade, Michelle M. Mezei
- 124** Procalcitonin Levels in Migraine Patients
Hale Turan, Bahriye Horasanli, Murat Ugur, Hande Arslan

129 The Thumb Rolling Test: A Novel Variant of the Forearm Rolling Test

Dennis A. Nowak

133 Effect of Lentiviral shRNA of Nogo Receptor on Rat Cortex Neuron Axon Outgrowth

Shengming Xu, Mingyuan Liu, Tao Zhang, Bitao Lv, Baifeng Liu, Wen Yuan

NEUROIMAGING HIGHLIGHTS

139 Reversible Wall Enhancement in Pediatric Cerebral Arteriopathy

Eric T. Payne, Xing-Chang Wei, Adam Kirton

141 Serial MR Imaging of Adult-Onset Rasmussen's Encephalitis

Myriam Irislimane, François Guilbert, Jean-Maxime Leroux, Lionel Carmant, Dang Khoa Nguyen

143 Preservation of Language in the Ataxic Infant in a Case of Cerebellar Agensis

Francois Dominique Jacob, Helly R. Goetz

145 Spinal Cord Infarction from an Unstable Aortic Plaque

Jamsheed A. Desai, Nicola Gambarotta

BRIEF COMMUNICATIONS

147 Cerebral Abscesses Resulting from H1N1 Influenza with Staphylococcal Co-Infection

Derek J. Roberts, John J.P. Kelly, Rajiv Midha, Aleksa Cenic

151 Double Myxopapillary Ependymomas of the Filum Terminale

Nancy McLaughlin, Marie-Christine Guiot, Line Jacques

155 Delayed MRI Findings in Herpes simplex Encephalitis

Yun Jiang, Liya Tang, Ping Gao, Shaosen Qin, Jingwen Jiang

158 A Case Report of an Isolated Pulmonary Arteriovenous Malformation Causing Stroke

Mohammed Alhazzaa, Mukul Sharma, Grant Stotts

161 Myopathy as the Initial Manifestation of Primary Amyloidosis

J. Keith, Z. Afshar-Ghotli, R. Roussev, B. Ernst, B. Young, J.M. Bilbao

165 Corpus Callosum Atrophy in a Patient with Neuromyelitis Optica

K. Alikhani, D.H. Lee, M. Kremenchutzky

168 An Unusual Inflammatory Response to Implanted Deep Brain Electrodes

Peter S. Hughes, Jerry P. Krcek, Douglas E. Hobson, Marc R. Del Bigio

MEMORIAM

171 Ellsworth C. (Buster) Alvord, Jr. (1923-2010)

Edward Stidworthy Johnson, Harvey B. Sarnat

ABSTRACT SUPPLEMENT

172 Canadian Association of Neuropathologists ABSTRACTS

Abstracts and unknown cases presented at the Fiftieth Annual Meeting in Toronto, Ontario, October 14th - 16th, 2010.

183 Books Received/Books Reviewed

186 Calendar of Events

A-3 CNSF Sponsors

A-9 Information for Authors

A-10 Advertisers Index

A-11 Board of Directors/Committee Chairs

A-14 Classified Ads

A-21 Congress-at-a-Glance

Canadian Neurological Sciences Federation / Fédération des sciences neurologiques du Canada

46th Annual Congress / 46e congrès annuel

June 15-17 juin/2011 Vancouver, British Columbia / Colombie Britannique

Canadian Neurological Sciences Federation




46th Annual Congress

Early Committed Sponsors

The Canadian Neurological Sciences Federation is pleased to recognize those Sponsors who, as of December 15, 2010 committed to supporting the 2011 Congress. These organizations partner with CNSF to determine the causes of, and develop treatment for diseases and injuries of the nervous system, and in the care of patients with these diseases and injuries.

PLATINUM



Merck Frosst Canada Ltd., Kirkland, Quebec

PLATINUM



THE EPILEPSY COMPANY™

PLATINUM



GOLD



Boehringer
Ingelheim

SILVER



SILVER



SUPPORTER



**NEUROLOGICAL SCIENCES
FOUNDATION OF CANADA**

- General Fund
- CNS - Don Paty Fund

If you and your organization would like more information, or would like to discuss how you can partner with CNSF and meaningfully connect with our Congress delegates, please call or email Brett Windle, Corporate Development Coordinator at (403) 229-9544 or brett-windle@cnsfederation.org.

VANCOUVER, B.C. CANADA

www.cnsfederation.org



Introducing

VIMPAT

POWER for Added Control

Demonstrated efficacy and safety profile in patients not adequately controlled with 1 to 3 concomitant AEDs

- ◆ The efficacy of VIMPAT was demonstrated in **3 pivotal studies** involving a total of 944 adult patients not adequately controlled by 1 to 3 concomitant AEDs – **84% of whom were taking 2 to 3 concomitant AEDs.**¹
- ◆ VIMPAT **significantly increased seizure control**, with a $\geq 50\%$ reduction in seizure frequency from baseline to the maintenance phase for **38-41% of patients** who added VIMPAT 400 mg/day to current therapy compared to placebo ($p \leq 0.01$) (responder rates in Chung *et al*: 38.3% VIMPAT vs. 18.3% placebo; in Halász *et al*: 40.5% vs. 25.8%; in Ben-Menachem *et al*: 41.1% vs. 21.9%).^{*1,2,3,4}
- ◆ Some of the most frequently reported **adverse reactions** (dizziness, nausea, and vision-related events, including diplopia and blurred vision) were **dose-related** and usually **mild to moderate** in intensity.¹

Since the first global approval of VIMPAT on August 29th 2008 through to February 28th 2010, there were approximately **25,899 patient-years of exposure to VIMPAT**¹

VIMPAT (lacosamide) is indicated as adjunctive therapy in the management of partial-onset seizures in adult patients with epilepsy (≥ 18 years of age) who are not satisfactorily controlled with conventional therapy. The clinical experience with VIMPAT in elderly patients with epilepsy (≥ 65 years of age) is limited. Caution should be exercised during dose titration and age-associated decreased renal clearance should be considered in elderly patients. The safety and efficacy of VIMPAT in pediatric patients (< 18 years of age) have not been established and its use in this patient population is not indicated.

VIMPAT is contraindicated in patients who are hypersensitive to the active substance or to any of the excipients and in patients with a history of, or presence of, second- or third-degree atrioventricular (AV) block. Patients with hypersensitivity to peanuts or soya should not take VIMPAT film-coated tablets.


VIMPAT should be used with caution in patients with known conduction problems (e.g. marked first-degree AV block, sick sinus syndrome without pacemaker), or with severe cardiac disease such as myocardial ischemia or heart failure. In such patients, obtaining an ECG before beginning VIMPAT, and after VIMPAT is titrated to steady-state, is recommended. Caution should be exercised when VIMPAT is given with other drugs that prolong the PR interval (e.g. carbamazepine, pregabalin, lamotrigine, beta-blockers, and class I antiarrhythmic drugs), as further PR prolongation is possible. In clinical trials of healthy subjects and patients with epilepsy, VIMPAT treatment was associated with PR interval prolongation in a dose-dependent manner. VIMPAT administration may predispose to atrial arrhythmias (atrial fibrillation or flutter), especially in patients with diabetic neuropathy

and/or cardiovascular disease. Patients should be made aware of the symptoms of atrial fibrillation and flutter (e.g. palpitations, rapid pulse, shortness of breath) and told to contact their physician should any of these symptoms occur.

Multiorgan hypersensitivity reactions (also known as Drug Rash with Eosinophilia and Systemic Symptoms, or DRESS), Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported with other anticonvulsants. If any of these hypersensitivity reactions are suspected, VIMPAT should be discontinued and alternative treatment started.

Treatment with VIMPAT has been associated with dizziness and ataxia, which could increase the occurrence of accidental injury or falls. Accordingly, patients should be advised not to drive a car or to operate other complex machinery or perform hazardous tasks until they are familiar with the effects of VIMPAT on their ability to perform such activities.

In controlled trials in patients with partial-onset seizures, VIMPAT treatment was associated with vision-related adverse events such as blurred vision and diplopia. Patients should be informed that if visual disturbances occur, they should notify their physician promptly. If visual disturbance persists, further assessment, including dose reduction and possible discontinuation of VIMPAT, should be considered. More frequent assessments should be considered for patients with known vision-related issues or those who are already routinely monitored for ocular conditions.







NEW FOR PATIENTS WITH EPILEPSY

VIMPAT is indicated as adjunctive therapy in the management of partial-onset seizures in adult patients (≥18 years) with epilepsy who are not satisfactorily controlled with conventional therapy.¹

A variety of strengths for you and your patients


- ◆ VIMPAT tablets are available in 4 strengths for convenient dosing.¹

Oral Tablets			
50 mg	100 mg	150 mg	200 mg
			

Tablets representative of actual size.

Convenient BID dosing, with or without food¹

- ◆ Depending on response and tolerability, the maintenance dose of VIMPAT can be increased by 50 mg twice daily every week, to a **maximum recommended dose of 400 mg/day**.¹



Adapted from the VIMPAT Product Monograph.¹
Please consult the Product Monograph for complete dose, dose adjustment, and administration instructions.

Suicidal ideation and behavior have been reported in patients treated with antiepileptic agents in several indications. All patients treated with antiepileptic drugs, irrespective of indication, should be monitored for signs of suicidal ideation and behavior and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behavior emerge. There are no studies with VIMPAT in pregnant women. Since the potential risk for humans is unknown, VIMPAT should not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus. It is unknown whether VIMPAT is excreted in human breast milk. Because many drugs are excreted into human milk, a decision should be made whether to discontinue nursing or to discontinue VIMPAT, taking into account the importance of the drug to the mother.

As with all antiepileptic drugs, VIMPAT should be withdrawn gradually (over a minimum of 1 week) to minimize the potential of increased seizure frequency.

In controlled clinical trials in patients with partial-onset seizures, some of the most frequently reported adverse reactions with VIMPAT treatment were dizziness (16% and 30% for 200 mg and 400 mg treatment groups, respectively, vs. 8% placebo), nausea (7% and 11% vs. 4%), and vision related events [diplopia (6% and 10% vs. 2%) and blurred vision (2% and 9% vs. 3%)]. They were dose-related and usually mild to moderate in intensity. The adverse events most commonly leading to discontinuation were dizziness, coordination abnormal, vomiting, diplopia, nausea, vertigo, and vision blurred. Please see the VIMPAT Product Monograph for full prescribing information.

* Responder rates (>50% reduction in seizure frequency) from baseline to maintenance period (intent to treat, ITT) of 3 randomized, double-blind, placebo-controlled, multicentre trials studying VIMPAT (lacosamide) as adjunctive therapy in adult patients with POS with or without secondary generalization. Patients were to have been taking a stable dosage regimen of one to three AEDs, with or without VNS in the 4 weeks before enrollment during the baseline period. Enrolled patients entered on 8-week baseline period to obtain baseline seizure frequency data and to determine eligibility for the double-blind period of the trial. At the beginning of the 4-week forced titration period, patients were started on either placebo or VIMPAT 100 mg/day. In the case of patients randomized to VIMPAT 400 mg/day, the dose was increased by 100 mg/day each week until the 400 mg/day dose was reached at the beginning of week 4. Patients randomized to 200 mg/day received placebo during the first 2 weeks of titration, were started on VIMPAT 100 mg/day at week 3, and the dose was increased to 200 mg/day at the beginning of week 4. Patients then entered a 12-week maintenance phase period.^{1,2,4}

References: 1. VIMPAT™ Product Monograph, UCB Canada Inc., September 23, 2010. 2. Chung S, Sperling MR, Biton V et al. Lacosamide as adjunctive therapy for partial onset seizures: A randomized controlled trial. *Epilepsia* 2010; 51(6):958-967. 3. Holász P, Kalvainen P, Mazurkiewicz-Baldzińska M, et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. *Epilepsia* 2009; 50(3):443-453. 4. Ben-Menachem E, Biton V, Jotuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. *Epilepsia* 2007; 48(7):1308-1317.

™VIMPAT is a trademark used under license from Harris FRC Corporation.

© 2010, UCB Canada Inc. All rights reserved. VIM-10-123

Date of preparation: December 2010


P. **VIMPAT**™
lacosamide

POWER for Added Control



*Fictitious patient. May not be representative of all fibromyalgia cases.



FACED WITH PAIN*

IN HER STRUGGLE WITH FIBROMYALGIA

First treatment indicated in Canada for adults
for the management of pain associated with
fibromyalgia¹

Pregabalin: first-line treatment for chronic
neuropathic pain²

DEMONSTRATED SIGNIFICANT RELIEF IN PAIN AND PAIN-RELATED SLEEP DIFFICULTIES IN FIBROMYALGIA¹

Demonstrated powerful, rapid and sustained pain relief^{1,3-5}

In fibromyalgia:

- In a 14 week study, LYRICA demonstrated significant pain reduction as early as week 1 ($p < 0.05$ for all doses). Mean changes in pain scores at the end of the study for LYRICA-treated patients were significantly greater versus placebo (300 mg/day, $n=183$: -1.75, $p=0.0009$; 450 mg/day, $n=190$: -2.03, $p < 0.0001$; 600 mg/day, $n=188$: -2.05, $p < 0.0001$; placebo, $n=184$: -1.04)³
- In another study of 26 weeks' duration of patients who initially responded to LYRICA during a 6-week, open-label phase, 68% of those who continued on their optimized dose ($n=279$) maintained a treatment response versus 39% of those on placebo ($n=287$). The time to loss of therapeutic response was longer in the LYRICA group ($p < 0.0001$)⁴

Also in neuropathic pain (NeP):

- Sustained pain relief (starting at week 2 for LYRICA 150-600 mg/day, $n=141$; $p < 0.05$ vs placebo, $n=65$) was demonstrated throughout a 12 week study in patients with DPN or PHN⁵

Demonstrated effective in relieving pain-related sleep difficulties^{1,6}

In fibromyalgia:

- In a 13 week study, LYRICA reduced overall MOS-Sleep Scale scores significantly more at the end of the study vs. placebo (300 mg/day -19.1, $p=0.0174$; 450 mg/day: -20.41, $p=0.0026$; 600 mg/day: -19.49, $p=0.0101$; placebo: -14.29)⁶

Also in NeP:

- LYRICA reduced sleep disturbances across several studies in DPN and PHN, of 8-12 weeks duration¹

Flexible dosing across all indications^{1†}

LYRICA (pregabalin) is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN) and spinal cord injury in adults. LYRICA may be useful in the management of central neuropathic pain in adults. LYRICA is indicated for the management of pain associated with fibromyalgia in adults. The efficacy of LYRICA in the management of pain associated with fibromyalgia for up to 6 months was demonstrated in a placebo-controlled trial in patients who had initially responded to LYRICA during a 6-week open-label phase.

LYRICA is contraindicated in patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.

The most commonly observed adverse events ($\geq 5\%$ and twice the rate as that seen with placebo) in the recommended dose range of 150 mg/day to 600 mg/day in PHN and DPN patients were: dizziness (9.0-37.0%), somnolence (6.1-24.7%), peripheral edema (6.1-16.2%), and dry mouth (1.9-14.9%) and were dose related; in spinal cord injury patients: somnolence (41.4%), dizziness (24.3%), asthenia (15.7%), dry mouth (15.7%), edema (12.9%), constipation (12.9%), amnesia (10.0%), myasthenia (8.6%), amblyopia (8.6%), and thinking abnormal (8.6%); in fibromyalgia patients: dizziness (37.5%), somnolence (18.6%), weight gain (10.6%), dry mouth (7.9%), blurred vision (6.7%), and peripheral edema (6.1%). In LYRICA-treated fibromyalgia patients, the most commonly observed dose-related adverse events were: dizziness (22.7-46.5%), somnolence (12.9-20.7%), weight gain (7.6-13.7%), peripheral edema (5.3-10.8%). The most commonly observed adverse events in the PHN, DPN, spinal cord injury and fibromyalgia patients were usually mild to moderate in intensity. Discontinuation rates due to adverse events for LYRICA and placebo, respectively, were 9% and 4% in DPN, 14% and 7% in PHN, 21% and 13% in spinal cord injury, and 20% and 11% in fibromyalgia. There was a dose-dependent increase in rate of discontinuation due to adverse events in fibromyalgia.

There have been post-marketing reports of angioedema in patients, some without reported previous history/episodes, including life-threatening angioedema with respiratory compromise. Caution should be exercised in patients with previous history/episodes of angioedema and in patients who are taking other drugs associated with angioedema.

In clinical trials and in post-marketing experience, there have been reports of patients, with or without previous history, experiencing renal failure alone or in combination with other medications. Caution is advised when prescribing to the elderly or those with any degree of renal impairment.

There have been post-marketing reports of events related to reduced lower gastrointestinal tract function (e.g., intestinal obstruction, paralytic ileus, and constipation) in patients, some without reported previous history/episode(s), during initial/acute and chronic treatment with LYRICA, primarily in combination with other medications that have the potential to produce constipation. Some of these events were considered serious and required hospitalization. In a number of instances, patients were taking opioid analgesics including tramadol. Caution should be exercised when LYRICA and opioid analgesics are used in combination, and measures to prevent constipation may be considered, especially in female patients and elderly as they may be at increased risk of experiencing lower gastrointestinal-related events.

Dosage reduction is required in patients with renal impairment (creatinine clearance <60 mL/min) and in some elderly patients as LYRICA is primarily eliminated by renal excretion.

Please see Prescribing Information for complete Warnings and Precautions, Adverse Reactions, Dosage and Administration and patient selection criteria.

† Please consult Prescribing Information for complete Dosage and Administration instructions.



Working together for a healthier world™

©2010
Pfizer Canada Inc.
Kirkland, Quebec
H9J 2M5

™Pfizer Inc, used under license
LYRICA® C.P. Pharmaceuticals International C.V.,
owner/Pfizer Canada Inc., Licensee



Editor-in-Chief/Rédacteur en chef

G. Bryan Young LONDON, ON

Associate Editors/Rédacteurs associés

J. Max Findlay EDMONTON, AB
Michael Shevell MONTREAL, QC
Timothy J. Benstead HALIFAX, NS
Mike Poulter LONDON, ON
Serge Gauthier VERDUN, QC
Robert Hammond LONDON, ON

Past Editors/Anciens rédacteurs en chef

Douglas W. Zochodne CALGARY, AB
James A. Sharpe TORONTO, ON
Robert G. Lee CALGARY, AB
Robert T. Ross WINNIPEG, MB
(Emeritus Editor, Founding Editor)

Editorial Board/Conseil d'éditorial

Jorge Burneo LONDON, ON
Richard Desbiens QUEBEC CITY, QC
David Fortin SHERBROOKE, QC
Mark Hamilton CALGARY, AB
Hans-Peter Hartung DUSSELDORF, GERMANY
Michael Hill CALGARY, AB
Alan C. Jackson WINNIPEG, MB
Daniel Keene OTTAWA, ON
Terence Myles CALGARY, AB
James Perry TORONTO, ON
Oksana Suchowersky CALGARY, AB
Brian Toyota VANCOUVER, BC
Brian Weinschenker ROCHESTER, MN, USA
Samuel Wiebe CALGARY, AB
Elaine Wirrell ROCHESTER, MN, USA

SECTION EDITORS/CONSEIL DE RÉDACTION

Neuroimaging Highlight/Neuroimagerie

David Pelz LONDON, ON

**Neuropathological Conference/Conférence
sur la neuropathologie**

Robert Hammond LONDON, ON

Book Review/Critiques de livres

Reflections/Reflets

Andrew Kirk SASKATOON, SK

Critically Appraised Topic Summaries

(CATS)

Jorge Burneo LONDON, ON
Mary Jenkins LONDON, ON

**Editorial Review Board/Conseil de
Revue d'éditorial**

Donald Brunet KINGSTON, ON
Lionel Carmant MONTREAL, QC
Colin Chalk MONTREAL, QC
K. Ming Chan EDMONTON, AB
Robert Chen TORONTO, ON
Mary Connolly VANCOUVER, BC
Joseph Dooley HALIFAX, NS
Paolo Federico CALGARY, AB
Daryl Fournay SASKATOON, SK
Hannah Glass SAN FRANCISCO, CA, USA
Alan Goodridge ST. JOHN'S, NL
Ian Grant HALIFAX, NS
Alan Guberman OTTAWA, ON
John Hurlbert CALGARY, AB
Manouchehr Javidan VANCOUVER, BC
Patrick McDonald WINNIPEG, MB
Martin McKeown VANCOUVER, BC
Joseph Megyesi LONDON, ON
Vivek Mehta EDMONTON, AB
Steven Miller VANCOUVER, BC
Neelan Pillay CALGARY, AB
Christopher Power EDMONTON, AB
Alex Rajput SASKATOON, SK
Jean Raymond MONTREAL, QC
Gary Redekop VANCOUVER, BC
Mark Sadler HALIFAX, NS
Harvey Sarnat CALGARY, AB
John Stewart VANCOUVER, BC
Jeanne Teitelbaum MONTREAL, QC
Eve Tsai OTTAWA, ON
Shannon Venance LONDON, ON
Matt Wheatley EDMONTON, AB
Jerome Yager EDMONTON, AB

Journal Staff - Calgary, AB

Dan Morin, *Chief Executive Officer*

Maggie McCallion, *Designer/
Production Coordinator*

Cindy Leschyshyn, *Editorial Coordinator*

**Advertising representative/Représentant de
publicité:**

Brett Windle

Corporate Development Coordinator
Tel (403) 229-9575 Fax (403) 229-1661
E-mail: brett-windle@cnsfederation.org

Printer/Imprimeur:

Unicom Graphics, 4501 Manitoba Road SE
Calgary, Alberta T2G 4B9

The official journal of / La Revue officielle de:

**The Canadian Neurological Society
La Société Canadienne de Neurologie**

**The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie**

**The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique**

**The Canadian Association of Child Neurology
L'Association Canadienne de Neurologie Pédiatrique**

The permanent secretariat for the four societies and the Canadian Neurological Sciences Federation is at:
Le secrétariat des quatre associations et du Fédération des sciences neurologiques du Canada est situé en permanence à:

7015 Macleod Trail SW, Suite 709
Calgary, Alberta, Canada T2H 2K6

The Canadian Journal of Neurological Sciences is published bi-monthly. The annual subscription rate for Individuals are: C\$120 (Canada), C\$140 (Foreign including USA). Subscription rates for Institutions are: C\$150 (Canada), C\$170 (Foreign including USA). See www.cjns.org for details. Single copies C\$30 each plus postage and handling. Communications should be sent to: Canadian Journal of Neurological Sciences, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Telephone (403) 229-9575; Fax (403) 229-1661. E-mail: journal@cjns.org; Web: www.cjns.org
COPYRIGHT© 2011 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. All rights reserved. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Postage paid at Calgary, Alberta.

Le Journal Canadien des Sciences Neurologiques est publié 6 fois par an. L'abonnement annuel est de 120 \$C (non-membres au Canada); 140 \$C (Etats Unis et ailleurs); l'abonnement annuel pour les institutions est de 150 \$C (non-membres au Canada); 170 \$C (Etats Unis et ailleurs); Voir www.cjns.org pour détails. Copie simple: 30 \$C plus affranchissement et manutention. Toutes les communications doivent être adressés à Journal Canadien des Sciences Neurologiques, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Téléphone (403) 229-9575; Fax (403) 229-1661. E-mail journal@cjns.org; Web: www.cjns.org. DROITS D'AUTEUR© 2011: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Tous droits réservés. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'autorisation du Journal Canadien des Sciences Neurologiques. Port payé à Calgary, Alberta.

This journal is indexed by / Cette Journal est cité et indexé dans: AgBio, BIOBASE, BioLab, BIOSIS Prev, CABS, ChemAb, CSA, CurAb, CurCont, E-psyche, EBSCO, Elsevier, EMBASE, ExcerptMed, IBZ, Index Medicus, Index to Dental Literature, Index to Scientific Reviews, Inpharma, Internationale Bibliographie der Rezensionen Geistes- und Sozialwissenschaftlicher Literatur, JW-N, MEDLINE, MetaPress, Mycolab, NRN, NSCI, PE&ON, Personal Alert, PsycFIRST, PsycInfo, Psychological Abstracts, PubMed, Reac, RefZh, SCI, SCOPUS, Swets, TOCPrem, Web of Science
ADVERTISING.

ISSN 0317 - 1671

